Lucia S.
- Country
- Spain
- Department
- Oncology
Research Overview
Data & Insights
Has run more than one trial at 2 of 30 partner sites.
Specializations
Hormone Receptor Positive Breast Cancer
The investigator concentrates on estrogen receptor‑positive, HER2‑negative disease, exploring endocrine strategies, CDK4/6 inhibition, and PI3K/AKT pathway modulation.
- Endocrine therapy resistance
- CDK4/6 inhibitor combinations
- PIK3CA‑mutated breast cancer
- ESR1‑mutated advanced disease
- Adjuvant endocrine therapy optimization
These topics support the development of precision approaches for patients with hormone‑driven tumors.
HER2‑Positive and HER2‑Low Breast Cancer
Research activities target both classic HER2‑positive malignancies and the emerging HER2‑low subgroup, emphasizing antibody‑drug conjugates and dual‑targeted regimens.
- HER2‑directed antibody‑drug conjugates
- Trastuzumab‑based combination therapies
- Brain metastasis management in HER2 disease
- HER2‑low IHC 0/1+ therapeutic strategies
- Sequential HER2‑targeted treatment lines
The focus advances therapeutic options across the HER2 expression spectrum.
Triple‑Negative Breast Cancer
In the triple‑negative arena, the investigator evaluates immunotherapy, novel ADCs, and biomarker‑driven combinations for patients with limited treatment alternatives.
- PD‑L1‑positive immunotherapy
- ADC development for TNBC
- Neoadjuvant and adjuvant checkpoint inhibition
- Biomarker‑guided therapy selection
- Combination regimens with chemotherapy
These efforts aim to improve outcomes in a high‑risk breast cancer subtype.
Melanoma and Non‑Small Cell Lung Cancer
The investigator’s portfolio includes advanced melanoma and non‑small cell lung cancer (NSCLC), with attention to targeted mutations and central nervous system involvement.
- KRAS‑G12C targeted therapy in NSCLC
- ROS1‑positive NSCLC with brain metastases
- Unresectable metastatic melanoma
- Immunotherapy for CNS disease
- Combination strategies with targeted agents
These studies address molecularly defined subsets and intracranial disease control.
Hematologic Malignancies and Other Solid Tumors
Beyond breast and thoracic oncology, the investigator engages in trials for B‑cell lymphomas and diverse solid tumors, focusing on novel agents and immunomodulation.
- Chronic lymphocytic leukemia and Richter’s transformation
- mantle‑cell lymphoma therapies
- Diffuse large B‑cell lymphoma investigational regimens
- Colorectal cancer with HER2 targeting
- Broad‑spectrum solid tumor ADC evaluation
The work expands therapeutic horizons across hematologic and solid tumor indications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.